Opinion statement
Solitary bone and extramedullary plasmacytomas are rare plasma cell proliferative disorders. Their diagnosis is based on histologic confirmation of monoclonal plasma cell infiltration of a single disease site and on the exclusion of systemic myeloma. For both entities, the treatment of choice is localized radiotherapy. With modern radiotherapy and with a total dose of at least 4000 cGy, the risk for local recurrence is less than 5%. There is no role for systemic chemotherapy in the management of these disorders. Approximately 30% of patients with solitary bone plasmacytoma (SBP) remain disease-free for several years; some of these patients may be cured. Patients with the best prognosis are those in whom the monoclonal protein disappears by 1 year after radiotherapy. The prognosis of patients with solitary extramedullary plasmacytoma (SEP) appears to be better than for patients with SBP because approximately 70% of patients with SEP remain disease-free at 10 years. With more sensitive staging procedures, the diagnosis of SBP and SEP may become less common, but the number of patients with prolonged stability and cure may increase.
Similar content being viewed by others
References and Recommended Reading
Dimopoulos MA, Moulopoulos LA, Maniatis A, et al.: Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000, 96:2037–2044.
Moulopoulos LA, Dimopoulos MA, Weber D, et al.: Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 1993, 11:1311–1315.
Dimopoulos MA, Kiamouris C, Moulopoulos LA: Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am 1999, 13:1249–1258.
Alexiou C, Kan RJ, Dietzfelbringer H, et al.: Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 1999, 85:2305–2314.
Miller FR, Lavertu P, Wanamaker JR, et al.: Plasmacytoma of the head and neck. Otolaryngol Head Neck Surg 1998, 119:614–618.
Hotz MA, Bosq J, Schwaab G, et al.: Extramedullary solitary plasmacytoma of the head and neck. Ann Oncol Rhinol Laryngol 1999, 108:495–500.
Shih LY, Dunn P, Leuing WM, et al.: Localized plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J Cancer 1995, 71:128–133.
Liebross RH, Ha CS, Cox JD, et al.: Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol 1999, 52:245–249.
Galieni P, Cavo M, Pulsoni A, et al.: Clinical outcome of extramedullary plasmacytoma. Haematologica 2000, 85:47–51.
Hussong JW, Perkins SL, Schnitzer B, et al.: Extramedullary plasmacytoma: a form of marginal zone cell lymphoma. Am J Clin Pathol 1999, 111:111–116.
Brinch L, Hannisdal E, Foss Abrahamsen A, et al.: Extramedullary plasmacytoma and solitary plasma cell tumors of bone. Eur J Haematol 1990, 44:131–134.
Bolek TW, Marcus RD, Mendenhall NP: Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys 1996, 36:329–333.
Frassica DA, Frassica FJ, Schray MF, et al.: Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys 1989, 16:43–48.
Liebross RH, Ha CS, Cox JD, et al.: Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 1998, 441:1063–1067.
Tsang RW, Gospodarowicz MK, Pintilie M, et al.: Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 2001, 50:113–120.
Dimopoulos MA, Coldstein J, Fuller L, et al.: Curability of solitary bone plasmacytoma. J Clin Oncol 1992, 10:587–590.
Galieni P, Cavo M, Avvisati G, et al.: Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol 1995, 6:687–691.
Holland J, Trenkner DA, Wasserman TH, et al.: Plasmacytoma: treatment results and conversion to myeloma. Cancer 1992, 69:1513–1517.
Ellis PA, Colls BM: Solitary plasmacytoma of bone: clinical features, treatment and survival. Hematol Oncol 1992, 10:207–211.
Wilder RB, Ha CS, Cox JD, et al.: Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Blood 2001, 98:849a.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dimopoulos, M.A., Hamilos, G. Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr. Treat. Options in Oncol. 3, 255–259 (2002). https://doi.org/10.1007/s11864-002-0015-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11864-002-0015-2